Register Login

Bleeding Disorders

Clinical Trial: Thrombin Generation Test Predicts Breakthrough Bleeding in Emicizumab Prophylaxis

Check with your medical library to obtain this clinical trial pre-publication: Pelzer FJ, Ertekin EI, Oleshko O, et al. Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis. Haematologica. 2025. doi: 10.3324/haematol.2025.288115. PMID: 41230703. Abstract Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against […]
read more

Anesthesiologists’ Approach to Perioperative Bleeding Management

ASH ’25 Report from Dr. Wolfgang Miesbach: Perioperative Bleeding Management: What 1,030+ U.S. Anesthesiologists Think About Current Challenges 50.6% practiced primarily at academic medical centers, while 42.3% worked in community hospitals, with additional representation from military/VA hospitals (3.7%). Nearly half (48.4%) worked at Level I trauma centers. The Progress… Prothrombin complex concentrates (PCCs) have become […]
read more

ASH 2025 Highlight: Beyond Immunosuppression: Two New Ways to Treat ITP

David Kuter gave this presentation at ASH 2025: Immune thrombocytopenic purpura is now recognized as a disorder characterized by both reduced production and increased destruction—this understanding drives treatment selection toward achieving complete remission, rather than just disease suppression. Increase Platelet Production The latest TPO receptor agonist, hetrombopag, now in phase 3 trials, offers a direct […]
read more

November 2025 QQ Summary: Historic Coag Factor Nomenclature

Our November Quick Question summary about Stuart-Prower Factor, linked to a 2023 article by Dave McGlasson about coagulation factor nomenclature. The summary and McGlasson’s article attracted a comment from Dr. Emmanuel Favaloro, which described the nomenclature of traditional and current VWF activity assays.  Dr. Favaloro cited three open-access articles on this topic (click to obtain the […]
read more

An Illustrated Review of Hemophilia B.

Click here for the illustrated open-access review, Hermans C, Astermark J, Trakymienė SŠ, Jiménez-Yuste, V. Haemophilia B: an illustrative review of current challenges and opportunities.  Res Prac Thromb Haemostasis, 2025;9, 103229. Abstract Background Hemophilia B is a genetic bleeding disorder caused by a deficiency of clotting factor IX, which presents unique challenges in clinical management. […]
read more

VWF Factor Assays in Caplacizumab Therapy

Check with your medical library or join ISTH to obtain Colpani P, Baronciani L, Mancini I, et al. Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction. J Thromb Haemost. 2025:S1538-7836(25)00545-8. doi: 10.1016/j.jtha.2025.08.020. PMID: 40915571. Abstract Background: Caplacizumab, a humanized […]
read more

A Case Study: Congenital Hypofibrinogenemia

Check your medical library for Wu Y, Qin K, Xiang L, et al. Congenital hypofibrinogenemia with bleeding risk: mutations in the FGA, FGB, and FGG genes. Lab Med. 2025:lmaf042. doi: 10.1093/labmed/lmaf042. PMID: 41233956. Abstract Introduction: Congenital hypofibrinogenemia is a genetic disorder caused by defects in the fibrinogen gene. We identified a case of congenital hypofibrinogenemia […]
read more